Menu Search
Equities

Onconetix Inc

J4T:DEU

Onconetix Inc

Actions
  • Price (EUR)0.192
  • Today's Change-0.04 / -17.24%
  • Shares traded15.40k
  • 1 Year change-75.16%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Onconetix, Inc. is a commercial stage biotechnology company. It is focused on the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. It has Entadfi, a Food and Drug Administration approved, oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, and Proclarix, an advanced proprietary diagnostic system for screening and diagnosis for men with indeterminate Prostate Specific Antigen (PSA) assessments in prostate cancer oncology. Entadfi is a once-daily, oral treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor. Proclarix is a next generation protein-based blood test that can be done with the same sample as a patient’s regular PSA test. Proteomedix is seeking to develop diagnostic, prognostic, and predictive tools to enable cancer management at all stages of disease progression.

  • Revenue in USD (TTM)758.90k
  • Net income in USD-45.68m
  • Incorporated2018
  • Employees12.00
  • Location
    Onconetix Inc201 E. Fifth Street, Suite 1900CINCINNATI 45202United StatesUSA
  • Phone+1 (513) 620-4101
  • Fax+1 (845) 818-3588
  • Websitehttps://onconetix.gcs-web.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ONCO:NAQ since
announced		Transaction
value
ProteoMediX LtdDeal completed18 Dec 202318 Dec 2023Deal completed-14.04%--
Wraser LLCAnnounced14 Jun 202314 Jun 2023Announced-73.89%3.50m
Data delayed at least 15 minutes, as of May 31 2024 21:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.